Merck's Keytruda in line for chemo-combo backing from NCCN by Tracy Staton Monday, October 24, 2016 Merck & Co. submitted data from a Keytruda-plus-chemo trial to an influential compendium of treatment guidelines, an analyst reports--and if it wins a listing, that could add to Keytruda's "halo effect" in other cancers.
